X4 Pharmaceuticals (NASDAQ:XFOR) Rating Reiterated by HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $5.00 price objective on the stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $5.00 price target on shares of X4 Pharmaceuticals in a research report on Friday, May 31st.

X4 Pharmaceuticals Stock Down 33.0 %

Shares of NASDAQ:XFOR opened at $0.67 on Friday. X4 Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $2.06. The company has a current ratio of 3.71, a quick ratio of 3.71 and a debt-to-equity ratio of 52.92. The stock’s 50-day moving average price is $1.03 and its 200-day moving average price is $0.98. The stock has a market capitalization of $112.54 million, a P/E ratio of -0.96 and a beta of 0.40.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). On average, equities analysts anticipate that X4 Pharmaceuticals will post -0.55 earnings per share for the current year.

Institutional Trading of X4 Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its position in shares of X4 Pharmaceuticals by 46.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after purchasing an additional 12,514 shares during the period. SG Americas Securities LLC lifted its holdings in X4 Pharmaceuticals by 38.8% in the fourth quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock worth $40,000 after buying an additional 13,328 shares during the period. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals in the third quarter worth about $678,000. Bain Capital Life Sciences Investors LLC boosted its position in X4 Pharmaceuticals by 6.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after acquiring an additional 955,196 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. grew its holdings in shares of X4 Pharmaceuticals by 76.0% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after acquiring an additional 1,500,000 shares during the period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.